The efficacy of remaxol as a hepatoprotective agent in long-term psychopharmacotherapy

Close metadata

Recommended articles:

Therapy of mental disorders in patients with hematological malignancies. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):127-136

Posttraumatic stress disorder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):58-68

Therapeutic targets of adolescent depression with attenuated symptoms of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):69-74

The use of systemic cytoprotective therapy in association with combination topical therapy on the basis of salicylic acid and glucocorticosteroids in psoriasis vulgaris. Russian Journal of Clinical Dermatology and Venereology. 2024;(2):168-172

Pulmonary distress syndrome in urgent surgery: A concept, pathogenesis, and fundamentals of treatment. Pirogov Russian Journal of Surgery. 2025;(2):77-85

Objective. Evaluation of the efficacy of psychopharmacotherapy with the hepatoprotector remaxol. Materials and methods. A study was conducted on 60 male patients diagnosed with «Paranoid schizophrenia, continuous progression type course» who received therapy for the underlying disease with traditional antipsychotics in a psychiatric inpatient setting. During the 12 days of the study, 30 patients (main group) received neuroleptic therapy in combination with intravenous infusions of remaxol (400.0 ml), the remaining 30 patients (control group) received «active placebo» (0.9% sodium chloride solution, 400.0 ml). Results and conclusion. A decrease in the frequency and severity of astheno-vegetative, dyspeptic, hemorrhagic, cholestatic syndromes and hepatomegaly was shown. The absence of side-effects along with an improvement in the general well-being of the patients is extremely important in long-term psychopharmacotherapy of psychiatric patients.

Keywords:

psychopharmacotherapy

neuroleptics

hepatoprotectors

remaxol

Authors:

Filippova N.V.

GBOU VPO "Saratovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. V.I. Razumovskogo, Saratov

Baryl'nik Iu.B.

GBOU VPO "Saratovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. V.I. Razumovskogo, Saratov

Shuldyakov A.A.

Razumovsky Saratov State Medical University, Saratov, Russia

List of references:

Sivolap YuP. The problem of hepatotoxicity in psychiatry. Psychiatry and Psychopharmacotherapy. 2013;1:29-32. (In Russ.)
Guo JJ, Wigle PR, Lammers K, Vu O. Comparison of potentially hepatotoxic drugs among major US drug compendia. Res Social Adm Pharm. 2005;1(3):460-479.
Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf. 2002;1(2):159-172.
Shpaner A, Li W, Ankoma-Sey V. Botero RC. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol. 2008;20(11):1106-1109.
Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28(9):1021-1041.
Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D. Hepatic tolerance of atypical antipsychotic drugs. Encephale. 2002;28(6):542-551.
Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiat. 2007;31(6):1255-1260.
Copur M, Erdogan A. Risperidone rechallenge for marked liver function test abnormalities in an autistic child. Recent Pat Endocr Metab Immune Drug Dis. 2011;5(3):237-239.
Denk H. Drug-induced liver injury. Verh Dtsch Ges Pathol. 2002;86:120-125.
Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN. Characterisation of human cytochrome P-450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013;41(3):651-658.
Hosomi H, Fukami T, Iwamura A, Nakajima M, Yokoi T. Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab Dispos. 2011;39(8):1388-1395.
Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer’s disease. Curr Pharm Des. 2004;10(3):231-251.
Safer DJ, Zito JM, Gardner JE. Pemoline hepatotoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiat. 2001;40(6):622-629.
Sedky K, Nazir R, Joshi A, Kaur G, Lippmann S. Which psychotropic medications induce hepatotoxicity? Gen Hosp Psychiat. 2012;34(1):53-61.
Rachauskas GS, Akulinin VN. The use of antral in patients with paranoid schizophrenia with therapeutic resistance, suffering from the pathology of the hepatobiliary system [Electronic resource]. Actual issues of modern psychiatry and narcology: Collection of scientific works of the Institute of Neurology, Psychiatry and Narcology of the Academy of Medical Sciences of Ukraine and Kharkiv Regional Clinical Psychiatric Hospital №3 (Saburova Dacha) dedicated to the 210^th anniversary of the Saburova dacha. Ed. Petryuka P.T., Bacherikova A.N. Kiev—Kharkov. 2010. V. 5. (In Russ) http://www.psychiatry.ua/books/actual/paper087.htm
Ivnitsky YuYu, Golovko AI, Sofronov GA. Succinic acid in the system of metabolic correction of the functional state and resistance of the organism. SPb.: Lan; 1998. (In Russ.)
Zubareva EV, Shuldyakov AA, Trubetskov AD, Lyapina EP, Satarova SA, Anashchenko AV. Metabolic therapy in the course of chronic brucellosis as a means for correction endotoxicosis and function anomaly of myocardium. Herald Mechnikov Saint-Petersburg State Medical Academy. 2008;3(28):93-95. (In Russ.)
Shuldyakov AA, Rechnik VN, Soboleva LA, Blinnikova EN, Savinova GA. Improvement of pathogenetic therapy for chronic hepatitis C. Epidemiology and Infectious Diseases. 2009;3:18-21. (In Russ.)
Sologub TV, Romantsov MG, Shuldyakov AA, Radchenko VG, Stelmach VV, Kovalenko AL, Esaulenko EV, Isakov VA. Reambirin as the medicine of pathogenetical therapy of acute and chronic viral liver dysfunction. Clinical Medicine. 2010;4:68-71. (In Russ.)
Sologub TV, Goryacheva LG, Suchanov DS, Romantsov MG, Antonova TV, Yakovlev AA, Radchenko VG, Shuldyakov AA, Rechnik VN, Suzdaltsev AA, Esaulenko EV, Maksimov SL, Baranova IP. Hepatoprotective activity of remaxol for chronic liver dysfunction (the materials of milticentre randomized clinical study). Clinical Medicine. 2010;1:62-66. (In Russ.)
Shuldyakov AA, Lyapina EP, Soboleva LA, Reshetnikov AA, Zubareva EV, Trubetskov AD, Anashchenko AV, Evdokimov AV. The use of cytoflavin for the treatment of chronic brucellosis. Clinical Medicine. 2011;2:56-58. (In Russ.)
Zaplutanov VA, Romantsov MG, Tikhonova EO, Almyasheva RZ, Lyapina EP, Pavelkina VF, Shuldyakov AA. Characteristics of Acute Intestinal Infection Process and Evaluation of Pathogenetic Therapy Efficacy. Antibiotics and Chemotherapy. 2012;9-10:17-24. (In Russ.)
Tikhonova EO, Lyapina EP, Shuldyakov AA. Efficacy of Pathogenetic Therapy in Patients with Acute Gastrointestinal Infections Using Succinic Acid Derivatives (Reamberin). Experimental and Clinical Pharmacology. 2013;76(1):11-13. (In Russ.)
Tikhonova EO, Lyapina EP, Shuldyakov AA, Satarova SA. Use of succinate-containing agents in the treatment of infectious diseases. Therapeutic Archive. 2016;11:121-127. (In Russ.)
Tikhonova EO, Lyapina EP, Shuldyakov AA, Gavrilova IB, Sretenskaya DA, Kuznetsov VI, Lisko OB. Reamberin in the complex therapy of acute intestinal infections. Experimental & Clinical Gastroenterology. 2017;2(138):77-85. (In Russ.)

Close metadata